Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction.
Twenty-nine patients with recent myocardial infarction were randomly allocated to a placebo group (n = 14) and to a group (n = 15) who received sulphinpyrazone, 4 x 200 mg daily for 7 days. Renal function significantly and transiently deteriorated in the sulphinpyrazone group compared to the placebo group. In the sulphinpyrazone group the 24 hour-urinary prostaglandin E2 and kallikrein excretion were suppressed. These data suggest that the decrease in renal function caused by sulphinpyrazone early after myocardial infarction could be mediated by an inhibition of renal prostaglandin and/or kallikrein-kinin synthesis.
D058186:Acute Kidney Injury / Q000139:chemically induced; D000368:Aged; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007610:Kallikreins / Q000652:urine; D007668:Kidney / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D011446:Prospective Studies; D011458:Prostaglandins E / Q000652:urine; D011897:Random Allocation; D013442:Sulfinpyrazone / Q000009:adverse effects* / Q000627:therapeutic use
D011458:Prostaglandins E; D003404:Creatinine; D007610:Kallikreins; D013442:Sulfinpyrazone